Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022
Voir/ Ouvrir
Date
2022-08-22Les auteurs
Prudden, Holly J.Achilles, Sharon L.
Schocken, Celina
Broutet, Nathalie
Canfell, Karen
Akaba, Hiroki
Basu, Partha
Bhatla, Neerja
Chirenje, Z. Mike
Delany-Moretlwe, Sinead
Denny, Lynette
Gamage, Deepa G.
Herrero, Rolando
Hutubessy, Raymond
Villa, Luisa Lina
Murillo, Raul
Schiller, John T.
Stanley, Margaret
Temmerman, Marleen
Zhao, Fanghui
Ogilvie, Gina
Kaslow, David C.
Dull, Peter
Gottlieb, Sami L.
Therapeutic HPV Vaccine PPC Expert Consultation Group
Auteur(s) d'entreprise
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Grupo de Oncología. Centro Javeriano de Oncología
Type
Artículo de revista
ISSN
0264-410X / 1873-2518 (Electrónico)
COAR
Artículo de revistaPartager cet enregistrement
Citación
Metadata
Afficher la notice complète
Documents PDF
Abstrait
The World Health Organization (WHO) global strategy to eliminate cervical cancer (CxCa) could result in >62 million lives saved by 2120 if strategy targets are reached and maintained: 90% of adolescent girls receiving prophylactic human papillomavirus (HPV) vaccine, 70% of women receiving twice-lifetime cervical cancer screening, and 90% of cervical pre-cancer lesions and invasive CxCa treated. However, the cost and complexity of CxCa screening and treatment approaches has hampered scale-up, particularly in low- and middle-income countries (LMICs), and new approaches are needed. Therapeutic HPV vaccines (TxV), which could clear persistent high-risk HPV infection and/or cause regression of pre-cancerous lesions, are in early clinical development and might offer one such approach. During October 2021 to March 2022, WHO, in collaboration with the Bill and Melinda Gates Foundation, convened a series of global expert consultations to lay the groundwork for understanding the potential value of TxV in the context of current CxCa prevention efforts and for defining WHO preferred product characteristics (PPCs) for TxV. WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper reports on the main discussion points and findings from the expert consultations. Experts identified several ways in which TxV might address challenges in current CxCa prevention programmes, but emphasized that the potential value of TxV will depend on their degree of efficacy and how quickly they can be developed and implemented relative to ongoing scale-up of existing interventions. Consultation participants also discussed potential use-cases for TxV, important PPC considerations (e.g., vaccine indications, target populations, and delivery strategies), and critical modelling needs for predicting TxV impact and cost-effectiveness.
Couverture temporaire
2021-2022Communauté
Mujeres con cáncer de cuello uterinoLien vers la ressource
https://www.sciencedirect.com/science/article/pii/S0264410X22009999?via%3DihubOrigine
Vaccine; Volumen 40 Número 41 , Páginas 5843 - 5855 (2022)
Google Analytics Statistics
Collections
- Artículos [13]